NASDAQ:XERS

Xeris Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy XERS

*Your capital is at risk

$5.89

-0.110 (-1.83%)

At Close: Jun 03, 2026

Xeris Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -36.34. In total, the insiders bought 4.12M and sold 1.83M XERS shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-36.34
● Buy	4.12M shares
● Sell	1.83M shares
52% Buy Activity Moderate Negative Correlation
Buy Signal Low Confidence Jan 30, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory negative Insider Power Score of -36.34. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jan 31, 2026 Sell	Common Stock F-InKind	Pieper Steven See Remarks	Officer	66 450 Value: $489.1K
Jan 31, 2026 Sell	Common Stock F-InKind	Hecht Beth See Remarks	Officer	98 375 Value: $724.0K
Jan 31, 2026 Sell	Common Stock F-InKind	Hecht Beth See Remarks	Officer	24 266 Value: $178.6K
Jan 30, 2026 Buy	Stock Option (Right to Buy) A-Award	Hecht Beth See Remarks	Officer	162 162 Value: $1.19M
Jan 30, 2026 Buy	Common Stock A-Award	Hecht Beth See Remarks	Officer	121 293 Value: $892.7K
Jan 30, 2026 Buy	Common Stock A-Award	Nguyen Anh Tu See Remarks	Officer	121 293 Value: $892.7K
Jan 30, 2026 Buy	Common Stock A-Award	Mcculloch Kevin See Remarks	Officer	168 463 Value: $1.24M
Jan 30, 2026 Buy	Stock Option (Right to Buy) A-Award	Shannon John Patrick Jr See Remarks	Officer	639 639 Value: $4.71M
Jan 30, 2026 Buy	Common Stock A-Award	Shannon John Patrick Jr See Remarks	Officer	478 436 Value: $3.52M
Jan 30, 2026 Buy	Stock Option (Right to Buy) A-Award	Mcculloch Kevin See Remarks	Officer	225 225 Value: $1.66M
Jan 30, 2026 Buy	Common Stock A-Award	Pieper Steven See Remarks	Officer	154 986 Value: $1.14M
Jan 30, 2026 Buy	Stock Option (Right to Buy) A-Award	Pieper Steven See Remarks	Officer	207 207 Value: $1.53M
Jan 30, 2026 Buy	Stock Option (Right to Buy) A-Award	Nguyen Anh Tu See Remarks	Officer	162 162 Value: $1.19M
Jan 08, 2026 Sell	Common Stock S-Sale	Mcculloch Kevin See Remarks	Officer	15 000 Value: $120.0K
Jan 05, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Shannon John Patrick Jr See Remarks	Officer	25 136 Value: $39.0K
Jan 05, 2026 Buy	Common Stock M-Exempt	Shannon John Patrick Jr See Remarks	Officer	2 900 Value: $11.4K
Jan 05, 2026 Buy	Common Stock M-Exempt	Shannon John Patrick Jr See Remarks	Officer	25 136 Value: $39.0K
Jan 05, 2026 Buy	Common Stock M-Exempt	Shannon John Patrick Jr See Remarks	Officer	64 265 Value: $99.6K
Jan 05, 2026 Sell	Common Stock S-Sale	Shannon John Patrick Jr See Remarks	Officer	24 907 Value: $176.3K
Jan 05, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Shannon John Patrick Jr See Remarks	Officer	2 900 Value: $11.4K
Jan 02, 2026 Sell	Common Stock S-Sale	Hecht Beth See Remarks	Officer	16 667 Value: $123.8K
Dec 19, 2025 Sell	Common Stock S-Sale	Johnson John Director	Director	135 400 Value: $977.0K
Dec 12, 2025 Sell	Common Stock S-Sale	Bormann-kennedy Barbara-jean Anne Director	Director	15 000 Value: $106.4K
Dec 01, 2025 Sell	Common Stock S-Sale	Hecht Beth See Remarks	Officer	16 667 Value: $116.8K
Nov 14, 2025 Buy	Stock Option (Right to Buy) M-Exempt	Shannon John Patrick Jr See Remarks	Officer	87 100 Value: $135.0K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT XERIS PHARMACEUTICALS INC

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhi...

Read Full Profile Here